TIPS-09 FIRST-IN-HUMAN PHASE 1 TRIAL OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF WSD0922-FU (NCT04197934): TRIAL IN PROGRESS

WSD0922-Fu is an oral, central nervous system (CNS)-penetrant, small molecule, ATP non-competitive, reversible EGFR inhibitor which potently inhibits EGFR aberrations specific to non-small cell lung cancer (NSCLC) and high-grade astrocytoma (HGA). MC1914 (NCT04197934, sponsored by Wayshine Biopharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kizilbash, Sani, Jaeckle, Kurt, Mrugala, Maciej, Allred, Jacob, Reid, Joel, Zhong, Wei, Burns, Terry, Giannini, Caterina, Sarkaria, Jann, Adjei, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: Trials in Progress
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402446/
http://dx.doi.org/10.1093/noajnl/vdad070.140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402446/
http://dx.doi.org/10.1093/noajnl/vdad070.140

Ejemplares similares